Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Post by proneon Feb 18, 2021 8:52am
155 Views
Post# 32593872

CBD skin care market to reach $3,484m with a CAGR of 24.80%

CBD skin care market to reach $3,484m with a CAGR of 24.80%

Global CBD Based Skin Care Market Could Exceed $3.45 Billion By 2026

16 minutes ago by PR Newswire
 

The personal care industry has witnessed a shift in consumer demand toward CBD infused skin & healthcare products over the past years and is expected to continue to grow for years to come.

The sale of American-produced CBD personal care products has been increased double fold owing to acceptance of multi-channel distribution by wholesales, private labelers, and other importers.

These stakeholders are developing a separate product lines of CBD infused personal care products.

This product lines include, among others, skin care, hand care, and lip moisturizer products. Companies are primarily marketing their products for health benefits associated with CBD in skin care products.

The innovative positioning of CBD infused skin care products coupled with effective distribution strategies are expected to boost the CBD skin care market growth well into the next decade.

A report from Allied Market Research projected that the global CBD skin care market size was valued at $633.6 million in 2018 and is anticipated to reach $3,484.00 million by 2026, with a CAGR of 24.80% during the forecast period.

Active companies in the markets this week include:
CAN B CORP. (OTCQB: CANB),
MediPharm Labs Corp.  (TSX: LABS),
Organigram Holdings Inc.  (TSX: OGI),
Tilray Inc. (NASDAQ: TLRY),
CV Sciences, Inc. (OTCQB: CVSI).

<< Previous
Bullboard Posts
Next >>